RuiMing Pharma Secures Tens of Millions in Series A Funding Led by KIP Capital to Advance Innovative Ophthalmic Drug Pipeline

PEDaily (ID: pedaily2012), December 7 — Today, Suzhou Raymon Pharmaceuticals Company, Ltd. announced the completion of its Series A financing round, raising tens of millions of RMB. The round was led by KIP Capital, with participation from Tuojin Capital, TigerYeah Capital, Shenzhen Sangel Venture Capital, and Shengding Equity Investment Fund Management Co., Ltd. The funds raised will be used for the regulatory filing of the AMD project and the development of subsequent pipeline products.

Raymon Pharma is a company dedicated to the development of innovative small-molecule ophthalmic drugs, focusing on medications for ocular diseases. It not only deeply engages in the treatment of blinding fundus diseases but also lays out multiple sustainable innovative pipelines in the field of ocular surface diseases. The company’s product portfolio involves research on various targets, mechanisms of action, and indications.

Raymon Pharma was established by Dr. Zhang Fei in Suzhou Industrial Park in March 2018 and completed its angel financing round in May of the same year. Founder Dr. Zhang Fei graduated from Columbia University in the United States and previously held key positions in new drug research and development at Merck and Novartis.

KIP Capital Management, regarding its investment in Raymon PharmaPartnerHu Jingzhi stated: "Currently, there is a large number of patients with macular degeneration both in China and worldwide. However, traditional treatments rely on intravitreal injections of monoclonal antibodies, which present many practical inconveniences. Raymon Pharma’s experienced team has identified significant opportunities in this sector. Their innovative eye drop formulation avoids the risk of infection, representing a typical new drug development model. We look forward to the early market launch of Raymon Pharma’s innovative products and its growth into a comprehensive ophthalmic treatment technology company, thereby benefiting patients widely."

Fu Hao, Vice President of Investment at KIP Capital, stated: “Ophthalmology is one of our key focus areas, as there are significant unmet needs in the industry. In the global landscape, there are many successful, specialized ophthalmic drug companies that are small yet highly focused. Raymon Pharma possesses valuable and extensive R&D experience in the development of small-molecule ophthalmic drugs. We are optimistic about the company’s continued dedication to this field and the future progress of its current product pipeline.”

Dr. Zhang Fei, the founder, stated: “Currently, the mainstream treatment for wet age-related macular degeneration (AMD) is intravitreal injection of large-molecule biologics. We focus on”Yu ZhiRaymon Pharma’s novel small-molecule ophthalmic drug features a unique compound design that enables topical eye-drop administration, with the active ingredient capable of penetrating ocular tissues to reach the fundus. Driven by factors such as global population aging, the worldwide market for ophthalmic medications is experiencing rapid growth. The development of new ophthalmic drugs is primarily focused on patient-friendly delivery methods, such as convenient and easy-to-use eye drops. The funds raised in this round will be used for the regulatory filing of the AMD project and the development of subsequent pipeline products. Recently, the follow-up pipeline projects have also achieved encouraging preclinical results. The successful completion of this financing round will comprehensively advance the company’s various product lines, marking a new milestone in the development of Raymon Pharma.